Bayer's Pipeline Progress Pushes Back Against the Roundup Shadow

Bayer advances pharma and ag despite legal overhang: Japan approves lung cancer drug, Kerendia sales surge 75%, analysts see upside.

The legal overhang from Roundup remains the dominant lens through which many investors view Bayer, but a steady drumbeat of operational news through August is quietly building a counter-narrative. Two regulatory and product milestones — one in oncology, one in cardiology — alongside fresh agricultural launches suggest the German conglomerate is advancing on multiple commercial fronts even as the September court calendar looms.

Japan Opens the Door for a First-in-Class Lung Cancer Therapy

On August 24, Japan's health ministry granted marketing approval to Sevabertinib, which will be sold under the brand name Hyrnuo. The drug targets patients with HER2-mutated non-small cell lung cancer and has been cleared for use across all treatment lines, regardless of prior therapy. That makes it the first targeted option available to this patient population in Japan, where physicians previously had to rely on less specific approaches.

The approval adds another pillar to Bayer's expanding oncology franchise, a division that is increasingly expected to carry weight alongside the company's established blockbuster drugs.

Kerendia's Momentum Tells a Broader Story

Just days later, at a cardiology congress in Munich, Bayer unveiled subgroup data from the Phase III FIND-CKD trial. The findings showed that finerenone, the active ingredient in Kerendia, slowed the decline of kidney function in patients with hypertensive nephropathy when added to standard therapy, compared with placebo.

The commercial picture is just as striking. First-half 2026 revenues for Kerendia jumped 75 percent year-on-year to EUR 603 million, positioning the drug as one of the fastest-growing assets in the pharma portfolio. That performance slots neatly into the group's second-quarter results, published in early August, which showed sales up 1.2 percent to EUR 10.87 billion — or 2.2 percent on a currency- and portfolio-adjusted basis.

Management used that earnings release to reaffirm its full-year guidance: adjusted EBITDA of EUR 9.6 billion to EUR 10.1 billion and core earnings per share between EUR 4.30 and EUR 4.90.

Agriculture Gets Its Own Shot of Momentum

The pharma headlines were complemented mid-week by the rollout of new crop science products, which Bayer explicitly tied to the mid-term targets it has set for that division. The launch did not go unnoticed in analyst circles: mwb research described the likelihood of hitting those goals as "increasingly credible," a verdict grounded in operational execution rather than mere corporate promises.

That twin-track progress matters because it addresses two of Bayer's three major divisions simultaneously. The company had already impressed markets in mid-August with better-than-expected quarterly numbers that shifted attention toward debt reduction and operational delivery. The latest pipeline news supplies the product-side evidence that the financial consolidation is not happening in a vacuum.

Analysts See Upside the Market Has Yet to Price

Equity researchers are taking note. On Thursday, JPMorgan reiterated its "Overweight" rating with a EUR 61 price target, pointing to operational execution and deleveraging as the key drivers. UBS, meanwhile, maintained a "Buy" recommendation with a EUR 62 target. Both sit comfortably above Friday's closing price of EUR 48.84, implying that the investment community sees room for the share price to catch up with the fundamental story.

So far, the market has been less enthusiastic. The stock slipped 1.3 percent on Friday and has spent recent sessions trading sideways, hovering near its 50-day moving average of EUR 48.73. Over the past month, the shares are down 1.9 percent. That muted reaction suggests investors are keeping their powder dry until the legal picture becomes clearer.

Still, the longer-term chart tells a different tale. Bayer shares have climbed roughly 32 percent since the start of the year, a rally that began with the recovery from the 52-week low of EUR 25.78 touched in November.

The September Date That Still Dominates

All eyes remain fixed on September 14, when a hearing related to the glyphosate settlement is scheduled. That date has a way of overshadowing near-term operational announcements, and the tepid share price response to the recent pipeline news reflects as much.

Yet the accumulation of approvals, launches, and clinical data points offers a reminder that Bayer's trajectory is not solely determined by the courtroom. The company is simultaneously building its pharma pipeline, refreshing its agricultural portfolio, and paying down debt — a combination that may eventually force the market to look beyond the legal noise and reassess the underlying business on its own merits.